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Abstract
Background: Gastric Helicobacter pylori is extremely common worldwide.
Objectives: The aim of this study was to assess the effectiveness of combination of Nigella sativa and honey (Dosin) in eradication
of gastric H. pylori infection.
Patients and Methods: Nineteen patients who had positive result for H. pylori infection by urea breath test (UBT) without a past
history of peptic ulcer, gastric cancer or gastrointestinal bleeding, were suggested to receive one teaspoon of the mixture of Dosin
(6 g/day of N. sativa as ground seeds and 12 g/day of honey) three times a day after meals for two weeks. The second UBT was used to
detect the presence of H. pylori four weeks after completion of the test. In addition, symptoms of dyspepsia were scored before and
after the study and analyzed with Wilcoxon signed-rank test.
Results: Fourteen patients completed the study. Negative UBT was observed in 57.1% (8/14) of participants after intervention. The
median and interquartile range (IQR) of total dyspepsia symptoms was significantly reduced from 5.5 (5 - 12) to 1 (0 - 4) (P = 0.005).
All the patients tolerated Dosin except for one who was excluded due to mild diarrhea. No serious adverse events were reported.
Conclusions: Dosin was concluded to be an anti H. pylori and an anti-dyspeptic agent. Further studies are recommended to investi-
gate the effect of Dosin plus antibiotics (concurrently or following another) on gastric H. pylori infection.
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1. Background
Gastric Helicobacter pylorus is extremely common
worldwide. The prevalence of H. pylori is estimated as
50.7% in Iran (the range is between 19.2% in Tehran and
74.2% in Mazandaran provinces) (1).
Gastritis, peptic ulcer and gastric cancer have been
ascribed to H. pylori (2). Eradication of H. pylori infec-
tion is important for prevention and treatment of gastro-
duodenal diseases, especially in developing countries with
high prevalence of H. pylori (3, 4).
Owing to the alarming rate of anti-H. pylori drug resis-
tance (14% - 45% for clarithromycin, 40% - 65% for metron-
idazole, and 2-37% for amoxicillin in Iran), eradication of H.
pylori remains a global challenge (2, 5, 6).
Patient’s compliance, medications side-effects, costs,
accessibility and feasibility of regimens are some impor-
tant factors in choosing medications (3, 7). Therefore, de-
velopment and testing of new safe, feasible and affordable
alternatives to these regimens is warranted.
Nigella sativa, from the Ranunculaceae family, is com-
monly known as black seed or black cumin. In Iranian tra-
ditional medicine (ITM), it is called “Shooniz” (8). It is tra-
ditionally used in India, Arabic countries, Europe and Iran
as food additive as well as a natural remedy for many dis-
orders like cough, jaundice and gastrointestinal disorders.
It is known to have digestive, laxative and gastric tonic ef-
fects and also be effective on bloating (8-12). There is a com-
mon Islamic belief that the black seed is a panacea (univer-
sal healer) which is a remedy for all ailments (9, 12, 13).
The antibacterial activity of the phenolic fraction of
N. sativa oil was first reported by Toppozada et al. (14).
Then, the anti-H. pylori activity of N. sativa was presented
by O’Mahony et al. (15) who found that the aqueous extract
of N. sativa had 100% bactericidal activity against H. pylori.
In 2009 and 2011, the anti-H. pylori effect of Iranian N. sativa
was demonstrated in two in vitro studies (16, 17). In 2013,
the urease enzyme inhibition potency of Iranian N. sativa
extract was presented (18).
The anti-H. pylori effect of N. sativa was shown in a clini-
cal trial in Saudi Arabia in 2010 and N. sativa seeds (2 g/day
for 14 days) were concluded to possess clinically useful anti-
H. pylori activity, comparable to 14 days of triple therapy
(amoxicillin, clarithromycin, omeprazole) (19).
Honey that is called “Angabin” in Persian and “Asal-
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al-Nahl” in ITM is known to be useful for gastrointestinal
problems like abdominal pain, bloating, jaundice and also
increasing the appetite (8).
The anti-H. pylori effect of honey has also been demon-
strated in some in vitro studies (20-22). The effects of honey
have been compared with clarithromycin in a rat model of
gastric ulcer. All honey samples demonstrated anti-H. py-
lori activity (23).
In Iran, the combination of N. sativa with honey (Dosin)
is used according to traditional (8) and Islamic medicine
(24) for alleviating gastrointestinal symptoms like abdom-
inal pain, bloating and diarrhea.
2. Objectives
The aim of the present pilot study was to investigate
the effectiveness of Dosin in eradication of H. pylori infec-
tion in patients with non-ulcer dyspepsia.
3. Patients andMethods
3.1. Preparation of Dosin
Mixture of Dosin was made in the department of phar-
macy, Tehran University of Medical Sciences. N. sativa and
honey were bought from Hamadan province, Iran. The
voucher specimen “PMP-735” was deposited to N. sativa in
the herbarium of faculty of pharmacy, Tehran University
of Medical Sciences, Tehran, Iran. N. sativa and honey were
mixed together in proportion of 1 (6 g/day of N. sativa as
ground seeds) to 2 (12 g/day of honey). The dosage of N.
sativa and honey in the mixture were chosen based on ITM
literature (8).
3.2. Patients and Protocol
The study was conducted in the gastroenterology
clinic of “Rasool-e-Akram” hospital (a specialized and sub-
specialized, referral, governmental hospital with 850 beds
in west of Tehran, Iran) in 2012. The medical ethics com-
mittee of the research institute for Islamic and comple-
mentary medicine approved the protocol (approval num-
ber and date: 1699/tm/p26, March 2012). The trial was regis-
tered in Iranian registry of clinical trials undet the number
IRCT201209041957N3.
Patients with gastrointestinal complaints and positive
urea breath test (UBT) were assessed and included accord-
ing to the inclusion/exclusion criteria after signing a writ-
ten informed consent. All the patients had positive results
for H. pylori infection by UBT. UBT was performed by the He-
liprobe® system made in Sweden, which was bought from
Beta company. The test was performed according to the in-
structions of the manufacturers.
Eligible patients were interviewed and underwent a
physical examination. A questionnaire regarding demo-
graphic data (age, gender, education and marital status)
and dyspepsia symptoms was filled for each patient. Diag-
nosis of dyspepsia was based on ROME III criteria which in-
clude one or more of the following symptoms: a burning
sensation or discomfort in the upper abdomen or lower
chest, sometimes relieved by food or antacids, early satia-
tion and bothersome postprandial fullness (25-27). Three
questions were used to assess the dyspepsia symptoms: (1-
pain or discomfort or burning in the upper abdomen or
lower chest sometimes relieved by food or antacids, 2- early
satiation, and 3- bothersome postprandial fullness). The
answer to each question of dyspepsia was scored between
0-6 according to the severity of symptoms (zero for ab-
sence of symptom during the past three months and 6 for
the severest symptom). The painting of the upper body ab-
domen and lower chest was added in the questionnaire to
help patients localizing the area of discomfort. Total score
of dyspepsia symptoms (0-18) presented the severity of dys-
pepsia.
Face and content validity of the questionnaire was eval-
uated by gastroenterologists and then was evaluated in a
pilot study on 20 patients. Test-retest was performed on
two separate occasions 4-7 days apart and the Pearson’s co-
efficient was 0.84. Furthermore, the internal consistency
of the questionnaire was measured using Cronbach’s al-
pha coefficient, which was 0.69.
Patients were excluded if: 1) they had past history
of peptic ulcer, gastric cancer or gastrointestinal bleed-
ing; 2) they had taken nonsteroidal anti-inflammatory
drugs (NSAIDs), corticosteroids, proton-pump inhibitors,
bismuth or antibiotics in the last four weeks before en-
doscopy; 3) they were pregnant or lactating mothers; 4)
they were intolerant or allergic to therapeutic regimens.
Written consents were obtained.
All the included patients were suggested to receive one
teaspoon of the mixture three times a day after meals for
two weeks. The patients were followed up weekly during
the two weeks of treatment with Dosin through telephone
contact. No antibiotic or proton pump inhibitors were al-
lowed during the study.
The second UBT was used to detect the presence of H.
pylori four weeks after the end of the treatment (2, 3, 19).
The follow-up information regarding improvement of
dyspepsia symptoms, appearance of side-effects and com-
pliance of the patients was documented in the file of each
patient.
The primary outcome measure was eradication of H.
pylori, which was considered to be achieved on the basis of
a negative UBT four weeks after the end of treatment. The
secondary outcome measure included changes in the clin-
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ical condition, assessed by an improvement in dyspepsia
scores.
Compliance was followed by a diary filled by the pa-
tients. Only patients who received more than 90% of
the prescribed medication were included in the statistical
analysis.
3.3. Statistical Analysis
The proportion of patients in whom eradication was
successful (negative UBT after intervention) was reported.
The severity of dyspepsia symptoms (total score of dys-
pepsia symptoms) before and after the treatment was pre-
sented as median and interquartile range (IQR), then com-
pared using the Wilcoxon signed rank test (because the
data did not have a normal distribution). P < 0.05 was con-
sidered as significant.
All the statistical analyses were performed using the
statistical package of social sciences (SPSS) version 17.
4. Results
Fifty eight available patients with gastrointestinal
complaints and positive UBT were assessed and 19 patients
were included. Five of the 19 patients discontinued the
study because of either traveling or loss of interest, and
one of them was excluded due to mild diarrhea. Figure
1 presents the process of sampling, follow-up and attri-
tions. Therefore, 14 patients, 6 (31.5%) males and 13 (68.5%)
females, finally completed the study.
Mean ± SD of age was 36.7 ± 10.3 years. Thirteen pa-
tients (92%) were married. Mean± SD of education was 12
± 2.1 years. At the end of the study, the UBT results were
negative for 8 (57.1%) participants (95% CI: 29.7-84.5).
The frequency of dyspepsia symptoms and their
changes during the study are shown in Table 1. The score
of dyspepsia symptoms significantly reduced after the in-
tervention. Postprandial acid regurgitation and malodor
of mouth were other complaints which were observed in
4 (21%) and 2 (10.5%) participants, respectively. Malodor of
mouth also improved after the intervention. None of the
participants experienced side-effects or worsening of the
symptoms during the study.
5. Discussion
The high frequency of H. pylori and the rising preva-
lence of antibiotic resistance, especially in developing
countries, emphasizes the need for discovery of new and
safer medications for treatment of H. pylori infection (3).
Anti-H. pylori effects of N. sativa and honey (separately)
have been approved in some in vitro and in vivo studies, as
mentioned before (16, 19, 28).
Table 1. Symptoms of Dyspepsia Before and After the Intervention
Number (%) of
patients with
this symptom
Median (IQR)
before
intervention
Median (IQR)
after
intervention
Epigastric
burning
sensation or
discomfort
15 (78.9) 5 (4 - 6) 0.5 (0 - 2)
Early satiation 7 (36.8) 0 (0 - 5) 0 (0 - 0.25)
Bothersome
postprandial
fullness
6 (31.5) 0 (0 - 5) 0 (0 - 0)
Total score of
dyspepsia
5.5 (5 - 12) 1 (0 - 4)
P value= 0.005a
aP value of Wilcoxon signed rank test.
The results of this study showed that Dosin eradicated
H. pylori in about 57% of infected patients. It is lower than
the eradication rate of triple therapy consisting of amoxi-
cillin, clarithromycin and omeprazole (reported about 75-
80% in developing countries) (2). However, it is almost
similar to the reported results of the study in Iran to com-
pare sequential with quadruple therapy. In the mentioned
study, the eradication rate was seen in 50.9% of patients
in sequential therapy (omeprazole, amoxicillin, each ad-
ministered twice daily for the first five days, followed by
omeprazole, clarithromycin and furazolidone, twice daily
for the remaining nine days) and 49.1% in routine four-
drug (omeprazole, clarithromycin, amoxicillin and bis-
muth twice daily for 14 days) therapeutic treatment (P >
0.05) (6).
In the study of Eyad M. Salem et al. in Saudi Arabia
in 2010, H. pylori eradication was 82.6, 47.6%, 66.7%, and
47.8% with triple therapy (clarithromycin, amoxicillin and
omeprazole), using 1, 2, and 3 g/day of N. sativa, respectively.
Eradication rates with 2 g N. sativa and triple therapy were
not statistically different from each other, whereas H. py-
lori eradication with other doses was significantly less than
that with triple therapy (P < 0.05) (19).
The difference of the results of our study with the study
in Saudi Arabia (19) may be due to expected differences in
resistance rate of H. pylori reported in different countries
(5, 29).
The seeds of N. sativa have been widely used in the treat-
ment of various disorders and it has been known as a mira-
cle herb among Muslims. It has been said that black seed is
the remedy for all diseases except death in a prophetic ha-
dith. It is also recommended for use on a regular basis in
Tibbe-Nabwi (prophetic medicine) (24).
A wide spectrum of its pharmacological actions has
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Figure 1. Flow Diagram of the Study
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been evaluated, which may include antidiabetic, an-
ticancer, immunomodulator, analgesic, antimicrobial,
anti-inflammatory, spasmolytic, bronchodilator, hepato-
protective, renal protective, gastro-protective, antioxidant
properties, etc. (12).
The anti-H. pylori action of N. sativa is probably due to
its urease inhibitory effect. H. pylori uses ammonia, the
urease enzyme product, to protect itself from the stomach
acidic condition (18).
N. sativa seeds contain a number of essential oils, in-
cluding thymoquinone, dihydrothymoquinone, and ter-
penes. It is revealed that most of the therapeutic properties
of N. sativa are due to the presence of thymoquinone which
is a major bioactive component of essential oil (12). Thymo-
quinone has gastroprotective mechanisms and anti-ulcer
activity via an inhibiting proton pump, acid secretion and
neutrophil infiltration, while enhancing mucin secretion
and nitric oxide production (30).
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The role of H. pylori infection in functional dyspepsia
is still controversial. Some studies indicated that eradica-
tion of H. pylori infection was associated with a significant
therapeutic effect on dyspepsia (31). Many guidelines now
recommend H. pylori eradication in uninvestigated sim-
ple dyspepsia following noninvasive diagnosis; others also
recommend treatment in functional dyspepsia (2).
Dosin successfully reduced the dyspepsia symptoms in
our study. Even if it is not so effective for eradicating H. py-
lori, it will be able to subside gastrointestinal symptoms in
non-ulcer dyspepsia.
In the study in Saudi Arabia (19), dyspepsia symptoms
improved in all the three groups of N. sativa (1, 2 and 3
g/day) to the same extent as in triple therapy. As mentioned
before, thymoquinone in N. sativa has an inhibitory effect
on proton pump and as a result has inhibitory activity on
gastric acid secretion (30).
Honey has long been known as a home remedy to alle-
viate dyspepsia. In addition, based on ITM literature, honey
is said to be warm and dry in nature and effective for gastric
symptoms (bloating, pain, loss of appetite and early satia-
tion), which are now called as dyspepsia (8).
The elements responsible for the antibacterial activity
of honey are not fully known, but have been attributed to
various polyphenolic compounds found in honey (propo-
lis, flavonoids, flavones, tannins) and to glucose oxidase
and osmosis (13). Molan et al. (31) attributed the antibac-
terial activity of honey to its content of glucose oxidase,
which liberates hydrogen peroxide when it is diluted.
Somerfield ascribed the antibacterial effect of honey to
the osmotic effect of its sugar content. Honey contains 38%
fructose, 31% glucose and 17% water, while its PH is 3.9 (32).
It may be concluded that the improvement of dyspep-
sia symptoms in our study was due to the N. sativa gastro-
protective and anti-secretory activities and also due to the
anti-dyspeptic effects of honey.
The weak point of this study was being a pilot study. It
was performed on a small sample size without any concur-
rent control groups and the results were compared to his-
torical controls. Hence, we suggest conducting a random-
ized controlled parallel clinical trial to compare the erad-
ication rate of Dosin with some different antibiotic regi-
mens. In addition, Dosin can be examined as the first regi-
men before taking the standard anti-H. pylori regimen and
then the eradication rate can be investigated. There is a
probability that the combination of Dosin with antibiotics
could decrease the possibility of emergence of resistant
colonies of H. pylori and improve the efficacy of antibiotic
regimens.
Further studies are also recommended to investigate
the effect of Dosin plus antibiotics or proton pump in-
hibitors (concurrently, following another or sequential
therapy) on gastric H. pylori infection.
Although even Dosin did not achieve complete eradi-
cation rate, it could be used as an alternative regimen in
patients unwilling to use triple or quadruple therapy regi-
mens.
5.1. Conclusion
Dosin, in a dose of 6 g/day of N. sativa seeds, possessed
anti-H. pylori activity. It was also concluded to be an ef-
fective anti-dyspeptic agent. Further studies with larger
sample size are recommended to investigate the effects of
Dosin plus antibiotics or proton pump inhibitors (concur-
rently or following another) on gastric H. pylori infection.
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